Healthcare [ 11/13 ] | Biotechnology [ 91/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 14, 23 | -1.18 Decreased by -883.33% | -1.13 Decreased by -4.42% |
| Aug 21, 23 | 0.96 Increased by +700% | -1.5 Increased by +164% |
| May 12, 23 | -0.11 Increased by +15.38% | -0.14 Increased by +21.43% |
| Mar 30, 23 | -0.1 Increased by +62.5% | -0.15 Increased by +30% |
| Nov 14, 22 | -0.12 Increased by +45.45% | -0.18 Increased by +33.33% |
| Aug 15, 22 | -0.16 Increased by +36% | -0.14 Decreased by -14.29% |
| May 16, 22 | -0.13 Increased by +56.67% | -0.17 Increased by +23.53% |
| Mar 28, 22 | -0.28 Decreased by -16.67% | -0.21 Decreased by -33.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -1.38 M Increased by +54.31% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | 1.09 M Increased by +128.15% | Increased by +N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -2.89 M Decreased by -4.87% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -2.87 M Increased by +50.84% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -3.03 M Increased by +29.8% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -3.86 M Increased by +12.98% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -2.76 M Increased by +42.97% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | -5.83 M Decreased by -68.07% | Decreased by N/A% Decreased by N/A% |
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.